PFIZER R 0437:STUDY OF FLUCONAZOLE + AMPHOTERICIN B IN TREATMENT OF C

这是一项随机、双盲研究，研究非中性粒细胞减少患者对念珠菌病的治疗及其后果，比较氟康唑与氟康唑联合两性霉素b的疗效、耐受性和安全性。氟康唑是一种新型口服有效的三唑类抗真菌药物。它已被发现对正常和免疫功能低下动物的真菌感染模型有效，包括小鼠和兔子的实验性隐球菌病和小鼠念珠菌病和组织浆菌病。此外，对伴有中枢神经系统隐球菌的艾滋病患者和伴有全身性念珠菌病的非中性粒细胞减少患者的人体研究也证实了氟康唑的临床疗效。在动物实验中，氟康唑通常不能像两性霉素B那样将真菌从所有组织中根除，但它能显著延长病原菌的寿命并减轻其组织负担。在这方面，氟康唑类似于咪唑和其他三唑。

This is a randomized, double-blind study of the treatment of candidemia and its consequences in non-neutropenic patients, comparing the efficacy, tolerance, and safety of fluconazole to that of fluconazole plus amphotericin B. Fluconazole is a novel orally effective triazole antifungal agent. It has been found to be effective in models of fungal infection in both normal and immunocompromised animals, including experimental cryptococcosis of mice and rabbits and murine candidiasis and histoplasmosis. In addition, human studies involving AIDS patients with CNS cryptococcus and non-neutropenic patients with systemic candidiasis also demonstrate clinical efficacy of fluconazole. In animal studies, fluconazole usually has not eradicated the fungus from all tissues, as can be accomplished with amphotericin B, but it has significantly prolonged life and decreased tissue burden of pathogenic fungi. In this respect, fluconazole resembles imidazoles and other triazoles.